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Biomarkers, particularly those with strong positive and negative predictive 
value, have many potential uses in the diagnosis and treatment of cancer, including 
monitoring treatment success, indicating disease progression and detecting early 
disease. One potentially powerful approach to finding biomarkers is to exploit patients' 
own immune systems, which produce humoral responses to cancer antigens released by 
their tumors due to alterations in protein expression, mutation, etc.... Antibodies to 
tumor antigens have been detected as early as several years before the clinical 
appearance of cancer. Although the specificity for these responses is high, typically only 
<20% of patients demonstrate a response to any given antigen, which has limited the 
usefulness of single antigen responses as biomarkers. The recent development of protein 
microarrays may offer an ideal tool for screening for immune response to tumor 
antigens. These arrays offer the advantage that hundreds to thousands of different 
proteins can be printed and    screened simultaneously and only require a few microliters 
of serum per assay.  
Prof. LaBaer‟s group (Harvard Institute Proteomics) has developed a novel 
method for producing protein microarrays called nucleic acid programmable protein 
arrays (NAPPA). Here, we propose adapting the NAPPA protein microarray technology 
for use in the rapid and efficient screening of sera from cancer patients for antibodies to 
6000 known and potential tumor antigens in a multiplex format in order to better 
characterize and identify new biomarkers related to drug treatment. For this purpose, 
patient´s samples pre- and post- chemotherapy have been included. A set of novel 
biomarkers suggest that approximately 30% of the patients show resistance agains 
chemotherapy pre- surgery, as it has been reported previously. For the validation of the 
possible biomarkers found in 20 different patients (pre- & post-chemotherapy), currently 
we are using iFISH and SNPs approaches with the main goal to correlate genomics and 
functional proteomics. 
